Published in Nat Commun on January 01, 2013
Inflammation. Neutrophil extracellular traps license macrophages for cytokine production in atherosclerosis. Science (2015) 2.93
Activation of the aryl hydrocarbon receptor dampens the severity of inflammatory skin conditions. Immunity (2014) 2.02
The role of dendritic cells in autoimmunity. Nat Rev Immunol (2013) 1.68
Trial Watch: Toll-like receptor agonists for cancer therapy. Oncoimmunology (2013) 1.35
Langerin(neg) conventional dendritic cells produce IL-23 to drive psoriatic plaque formation in mice. Proc Natl Acad Sci U S A (2013) 1.24
Trial watch: Dendritic cell-based interventions for cancer therapy. Oncoimmunology (2013) 1.09
Trial Watch: Toll-like receptor agonists in oncological indications. Oncoimmunology (2014) 0.96
Understanding the biology of antigen cross-presentation for the design of vaccines against cancer. Front Immunol (2014) 0.93
Dual Inhibition of TNFR1 and IFNAR1 in Imiquimod-Induced Psoriasiform Skin Inflammation in Mice. J Immunol (2015) 0.89
Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy. Oncoimmunology (2015) 0.85
IL-6 regulates neutrophil microabscess formation in IL-17A-driven psoriasiform lesions. J Invest Dermatol (2013) 0.83
Tumor necrosis factor superfamily in innate immunity and inflammation. Cold Spring Harb Perspect Biol (2014) 0.82
Unprocessed Interleukin-36α Regulates Psoriasis-Like Skin Inflammation in Cooperation With Interleukin-1. J Invest Dermatol (2015) 0.80
Topical imiquimod yields systemic effects due to unintended oral uptake. Sci Rep (2016) 0.78
Plasmacytoid dendritic cells orchestrate TLR7-mediated innate and adaptive immunity for the initiation of autoimmune inflammation. Sci Rep (2016) 0.78
Efficacy of imiquimod-based transcutaneous immunization using a nano-dispersed emulsion gel formulation. PLoS One (2014) 0.77
IL-6 Signaling in Myelomonocytic Cells Is Not Crucial for the Development of IMQ-Induced Psoriasis. PLoS One (2016) 0.77
TLR7-mediated skin inflammation remotely triggers chemokine expression and leukocyte accumulation in the brain. J Neuroinflammation (2016) 0.77
Original Research: Different imiquimod creams resulting in differential effects for imiquimod-induced psoriatic mouse models. Exp Biol Med (Maywood) (2016) 0.77
Inhibition of keratinocyte proliferation by phospholipid-conjugates of a TLR7 ligand in a Myc-induced hyperplastic actinic keratosis model in the absence of systemic side effects. Eur J Dermatol (2013) 0.77
CD69 controls the uptake of L-tryptophan through LAT1-CD98 and AhR-dependent secretion of IL-22 in psoriasis. Nat Immunol (2016) 0.77
Neutrophils in animal models of autoimmune disease. Semin Immunol (2016) 0.76
SIRT1 Activation Ameliorates Aldara-Induced Psoriasiform Phenotype and Histology in Mice. J Invest Dermatol (2015) 0.75
Effects of Human Mesenchymal Stem Cells Transduced with Superoxide Dismutase on Imiquimod-Induced Psoriasis-Like Skin Inflammation in Mice. Antioxid Redox Signal (2015) 0.75
Imiquimod Treatment Causes Systemic Disease in Mice Resembling Generalized Pustular Psoriasis in an IL-1 and IL-36 Dependent Manner. Mediators Inflamm (2016) 0.75
IMQ Induced K14-VEGF Mouse: A Stable and Long-Term Mouse Model of Psoriasis-Like Inflammation. PLoS One (2015) 0.75
Imiquimod has strain-dependent effects in mice and does not uniquely model human psoriasis. Genome Med (2017) 0.75
The Snowballing Literature on Imiquimod-Induced Skin Inflammation in Mice: A Critical Appraisal. J Invest Dermatol (2016) 0.75
Complement C3 exacerbates imiquimod-induced skin inflammation and psoriasiform dermatitis. J Invest Dermatol (2016) 0.75
NFATc1 supports imiquimod-induced skin inflammation by suppressing IL-10 synthesis in B cells. Nat Commun (2016) 0.75
Strategies for designing synthetic immune agonists. Immunology (2016) 0.75
Anticancer effects of the microbiome and its products. Nat Rev Microbiol (2017) 0.75
The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell (2006) 33.94
Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function. Immunity (1998) 18.12
Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol (2002) 13.10
Bacterial RNA and small antiviral compounds activate caspase-1 through cryopyrin/Nalp3. Nature (2006) 9.77
An essential function for the nuclear receptor RORgamma(t) in the generation of fetal lymphoid tissue inducer cells. Nat Immunol (2003) 8.23
The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat Med (2011) 8.00
Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling. Nat Immunol (2011) 6.53
RORgammat and commensal microflora are required for the differentiation of mucosal interleukin 22-producing NKp46+ cells. Nat Immunol (2008) 5.91
Active caspase-1 is a regulator of unconventional protein secretion. Cell (2008) 5.89
The IL-1 family: regulators of immunity. Nat Rev Immunol (2010) 4.65
Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis. J Immunol (2009) 4.63
Pivotal role of dermal IL-17-producing γδ T cells in skin inflammation. Immunity (2011) 3.75
S100A8 and S100A9 in inflammation and cancer. Biochem Pharmacol (2006) 3.67
Keratinocyte-fibroblast interactions in wound healing. J Invest Dermatol (2007) 3.51
Caspase-1-induced pyroptotic cell death. Immunol Rev (2011) 3.47
Human keratinocytes express functional Toll-like receptor 3, 4, 5, and 9. J Invest Dermatol (2006) 3.06
Immune defence in mice lacking type I and/or type II interferon receptors. Immunol Rev (1995) 2.97
The inflammasome mediates UVB-induced activation and secretion of interleukin-1beta by keratinocytes. Curr Biol (2007) 2.57
MyD88-mediated signaling prevents development of adenocarcinomas of the colon: role of interleukin 18. J Exp Med (2010) 2.57
Rorγt+ innate lymphocytes and γδ T cells initiate psoriasiform plaque formation in mice. J Clin Invest (2012) 2.40
c-Jun and JunB antagonistically control cytokine-regulated mesenchymal-epidermal interaction in skin. Cell (2000) 2.35
Tumoricidal activity of TLR7/8-activated inflammatory dendritic cells. J Exp Med (2007) 2.20
Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream. J Am Acad Dermatol (1999) 2.12
Cloning and characterization of a sub-family of human toll-like receptors: hTLR7, hTLR8 and hTLR9. Eur Cytokine Netw (2000) 2.11
Functional characterization of the rat chemokine KC and its importance in neutrophil recruitment in a rat model of pulmonary inflammation. J Immunol (1995) 2.01
Psoriasis triggered by toll-like receptor 7 agonist imiquimod in the presence of dermal plasmacytoid dendritic cell precursors. Arch Dermatol (2004) 1.96
IL-22 is required for imiquimod-induced psoriasiform skin inflammation in mice. J Immunol (2011) 1.92
Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential. Clin Exp Dermatol (2002) 1.88
Mechanisms underlying imiquimod-induced regression of basal cell carcinoma in vivo. Arch Dermatol (2003) 1.81
The primary histologic lesion of seborrheic dermatitis and psoriasis. J Invest Dermatol (1966) 1.74
Large induction of keratinocyte growth factor expression by serum growth factors and pro-inflammatory cytokines in cultured fibroblasts. Oncogene (1994) 1.71
Imiquimod: mode of action. Br J Dermatol (2007) 1.70
Cutting edge: generation of IL-18 receptor-deficient mice: evidence for IL-1 receptor-related protein as an essential IL-18 binding receptor. J Immunol (1999) 1.69
Imiquimod clears tumors in mice independent of adaptive immunity by converting pDCs into tumor-killing effector cells. J Clin Invest (2012) 1.66
The small antitumoral immune response modifier imiquimod interacts with adenosine receptor signaling in a TLR7- and TLR8-independent fashion. J Invest Dermatol (2006) 1.48
Disease-independent skin recruitment and activation of plasmacytoid predendritic cells following imiquimod treatment. J Natl Cancer Inst (2005) 1.46
Paracrine regulation of keratinocyte proliferation and differentiation. Trends Cell Biol (2001) 1.43
Type I interferon negatively controls plasmacytoid dendritic cell numbers in vivo. J Exp Med (2011) 1.39
Critical role of neutrophils for the generation of psoriasiform skin lesions in flaky skin mice. J Invest Dermatol (2000) 1.32
Imiquimod, a topical immune response modifier, induces migration of Langerhans cells. J Invest Dermatol (2000) 1.28
Imiquimod enhances IFN-gamma production and effector function of T cells infiltrating human squamous cell carcinomas of the skin. J Invest Dermatol (2009) 1.13
Effects of a novel topical immunomodulator, imiquimod, on keratinocyte cytokine gene expression. Lymphokine Cytokine Res (1994) 1.11
Imiquimod: in superficial basal cell carcinoma. Am J Clin Dermatol (2005) 1.08
Imiquimod 5 percent cream and the treatment of cutaneous malignancy. Dermatol Online J (2004) 1.03
Advances in the use of topical imiquimod to treat dermatologic disorders. Ther Clin Risk Manag (2008) 1.01
Cancer-testis antigens and immunosurveillance in human cutaneous squamous cell and basal cell carcinomas. Clin Cancer Res (2010) 1.00
Interleukin-1, inflammasomes and the skin. Eur J Cell Biol (2010) 0.99
Generalized psoriasis induced by topical treatment of actinic keratosis with imiquimod. Int J Dermatol (2006) 0.97
Imiquimod in basal cell carcinoma: how does it work? Br J Dermatol (2003) 0.86
Granulocyte-macrophage colony-stimulating factor in psoriasis. Dermatologica (1990) 0.86
Efficacy of imiquimod for the expression of Bcl-2, Ki67, p53 and basal cell carcinoma apoptosis. Br J Dermatol (2004) 0.84
Keratins and skin disorders. Cell Biol Int (1996) 0.82
Expression of Fas-receptor on basal cell carcinomas after treatment with imiquimod 5% cream or vehicle. Br J Dermatol (2003) 0.80
Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med (2015) 14.71
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature (2010) 14.62
High-throughput oncogene mutation profiling in human cancer. Nat Genet (2007) 12.68
Wound repair and regeneration. Nature (2008) 12.30
Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med (2012) 11.72
Integrative analysis of the melanoma transcriptome. Genome Res (2010) 8.46
MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci U S A (2009) 6.58
Modeling genomic diversity and tumor dependency in malignant melanoma. Cancer Res (2008) 5.95
Active caspase-1 is a regulator of unconventional protein secretion. Cell (2008) 5.89
Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med (2014) 5.65
Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature (2013) 4.90
T-helper-1-cell cytokines drive cancer into senescence. Nature (2013) 4.47
MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol (2013) 4.26
The Genetic Evolution of Melanoma from Precursor Lesions. N Engl J Med (2015) 4.24
Cancer as an overhealing wound: an old hypothesis revisited. Nat Rev Mol Cell Biol (2008) 4.05
Resting dendritic cells induce peripheral CD8+ T cell tolerance through PD-1 and CTLA-4. Nat Immunol (2005) 4.01
In vivo switching of human melanoma cells between proliferative and invasive states. Cancer Res (2008) 3.66
Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet (2008) 3.62
Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature. Pigment Cell Res (2006) 3.42
The adaptor protein FADD protects epidermal keratinocytes from necroptosis in vivo and prevents skin inflammation. Immunity (2011) 3.10
Selective survival of naturally occurring human CD4+CD25+Foxp3+ regulatory T cells cultured with rapamycin. J Immunol (2007) 3.09
Potential risks of bone marrow cell transplantation into infarcted hearts. Blood (2007) 2.97
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol (2008) 2.88
Multifocal epithelial tumors and field cancerization from loss of mesenchymal CSL signaling. Cell (2012) 2.75
The inflammasome mediates UVB-induced activation and secretion of interleukin-1beta by keratinocytes. Curr Biol (2007) 2.57
Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. Clin Cancer Res (2011) 2.52
NY-ESO-1: review of an immunogenic tumor antigen. Adv Cancer Res (2006) 2.44
Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma. J Clin Oncol (2012) 2.42
Red blood cells express a functional endothelial nitric oxide synthase. Blood (2005) 2.30
Epidermal progenitors give rise to Merkel cells during embryonic development and adult homeostasis. J Cell Biol (2009) 2.24
Engraftment of engineered ES cell-derived cardiomyocytes but not BM cells restores contractile function to the infarcted myocardium. J Exp Med (2006) 2.23
Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients. Proc Natl Acad Sci U S A (2006) 2.19
Integrin-linked kinase controls microtubule dynamics required for plasma membrane targeting of caveolae. Dev Cell (2010) 2.17
Novel MITF targets identified using a two-step DNA microarray strategy. Pigment Cell Melanoma Res (2008) 2.14
Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study. Lancet Oncol (2013) 2.13
Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: correlation with antibody responses. Proc Natl Acad Sci U S A (2003) 2.09
Human CD271-positive melanoma stem cells associated with metastasis establish tumor heterogeneity and long-term growth. Cancer Res (2011) 2.08
A crucial role of beta 1 integrins for keratinocyte migration in vitro and during cutaneous wound repair. Development (2002) 2.04
The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. PLoS One (2013) 2.01
c-Met is essential for wound healing in the skin. J Cell Biol (2007) 1.98
Nrf2 transcription factor, a novel target of keratinocyte growth factor action which regulates gene expression and inflammation in the healing skin wound. Mol Cell Biol (2002) 1.97
Psoriasis triggered by toll-like receptor 7 agonist imiquimod in the presence of dermal plasmacytoid dendritic cell precursors. Arch Dermatol (2004) 1.96
Hypoxia contributes to melanoma heterogeneity by triggering HIF1α-dependent phenotype switching. J Invest Dermatol (2013) 1.91
Potentiation of fibroblast growth factor activity by synthetic heparin oligosaccharide glycodendrimers. Chem Biol (2007) 1.89
EGFR signalling as a negative regulator of Notch1 gene transcription and function in proliferating keratinocytes and cancer. Nat Cell Biol (2008) 1.88
Mechanisms underlying imiquimod-induced regression of basal cell carcinoma in vivo. Arch Dermatol (2003) 1.81
Oxidative stress in normal and impaired wound repair. Pharmacol Res (2008) 1.80
Granulomatous mycosis fungoides and granulomatous slack skin: a multicenter study of the Cutaneous Lymphoma Histopathology Task Force Group of the European Organization For Research and Treatment of Cancer (EORTC). Arch Dermatol (2008) 1.78
Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032). Eur J Cancer (2011) 1.78
Induction of genes mediating interferon-dependent extracellular trap formation during neutrophil differentiation. J Biol Chem (2004) 1.78
Impaired liver regeneration in Nrf2 knockout mice: role of ROS-mediated insulin/IGF-1 resistance. EMBO J (2007) 1.76
Activating mutations of the tyrosine kinase receptor FGFR3 are associated with benign skin tumors in mice and humans. Hum Mol Genet (2005) 1.74
Activated Nrf2 impairs liver regeneration in mice by activation of genes involved in cell-cycle control and apoptosis. Hepatology (2014) 1.73
Inducible transgenic mice reveal resting dendritic cells as potent inducers of CD8+ T cell tolerance. Immunity (2003) 1.72
MRP8 and MRP14 control microtubule reorganization during transendothelial migration of phagocytes. Blood (2004) 1.71
Attenuation of allergic contact dermatitis through the endocannabinoid system. Science (2007) 1.70
Dyscrasias with "undetermined significance". Arch Dermatol (2005) 1.70
Priming of CTLs by lymphocytic choriomeningitis virus depends on dendritic cells. J Immunol (2005) 1.70
Increased IgE-dependent mast cell activation and anaphylactic responses in mice lacking the calcium-activated nonselective cation channel TRPM4. Nat Immunol (2007) 1.68
Follistatin regulates enamel patterning in mouse incisors by asymmetrically inhibiting BMP signaling and ameloblast differentiation. Dev Cell (2004) 1.65
Oligonucleotide array-CGH identifies genomic subgroups and prognostic markers for tumor stage mycosis fungoides. J Invest Dermatol (2009) 1.65
Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer. J Clin Oncol (2004) 1.64
Integrin-linked kinase is required for epidermal and hair follicle morphogenesis. J Cell Biol (2007) 1.63
Consistent expression of the stem cell renewal factor BMI-1 in primary and metastatic melanoma. Int J Cancer (2007) 1.62
An important role of lymphatic vessel activation in limiting acute inflammation. Blood (2011) 1.62
Psoriasiform dermatitis is driven by IL-36-mediated DC-keratinocyte crosstalk. J Clin Invest (2012) 1.58
Skin problems associated with pegylated liposomal doxorubicin-more than palmoplantar erythrodysesthesia syndrome. Eur J Dermatol (2008) 1.58
A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. J Immunol (2007) 1.56
Inhibition of fibroblast activation protein and dipeptidylpeptidase 4 increases cartilage invasion by rheumatoid arthritis synovial fibroblasts. Arthritis Rheum (2010) 1.52
Basic fibroblast growth factor controls migration in human mesenchymal stem cells. Stem Cells (2006) 1.52
Recombinant measles virus induces cytolysis of cutaneous T-cell lymphoma in vitro and in vivo. J Invest Dermatol (2006) 1.52
WHO/EORTC classification of cutaneous lymphomas 2005: histological and molecular aspects. J Cutan Pathol (2005) 1.51
Radiotherapy promotes tumor-specific effector CD8+ T cells via dendritic cell activation. J Immunol (2012) 1.48
Sox10 promotes the formation and maintenance of giant congenital naevi and melanoma. Nat Cell Biol (2012) 1.48
Beyond wavy hairs: the epidermal growth factor receptor and its ligands in skin biology and pathology. Am J Pathol (2008) 1.47
Disease-independent skin recruitment and activation of plasmacytoid predendritic cells following imiquimod treatment. J Natl Cancer Inst (2005) 1.46
Special considerations for stage IV melanoma during pregnancy. Arch Dermatol (2005) 1.46
Cancer-related serological recognition of human colon cancer: identification of potential diagnostic and immunotherapeutic targets. Cancer Res (2002) 1.46
The role of fibroblast growth factor receptor 2b in skin homeostasis and cancer development. EMBO J (2007) 1.45
Nrf transcription factors in keratinocytes are essential for skin tumor prevention but not for wound healing. Mol Cell Biol (2006) 1.45
Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition. J Clin Oncol (2012) 1.45
Cerivastatin activates endothelial calcium-activated potassium channels and thereby modulates endothelial nitric oxide production and cell proliferation. J Am Soc Nephrol (2004) 1.45
ADAMTS1 proteinase is up-regulated in wounded skin and regulates migration of fibroblasts and endothelial cells. J Biol Chem (2005) 1.45
Comparison of contractile behavior of native murine ventricular tissue and cardiomyocytes derived from embryonic or induced pluripotent stem cells. FASEB J (2010) 1.45